Compare Cassava Sciences Inc (FLNA) vs iShares Russell 2000 ETF (IWM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs iShares Russell 2000 ETF — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while iShares Russell 2000 ETF trades at $278.66 (market cap $77.70B). The key difference: iShares Russell 2000 ETF is far larger — about 1972.1× Cassava Sciences Inc's market cap, and iShares Russell 2000 ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and iShares Russell 2000 ETF for 83 Days on average.
| FLNA | IWM | |
|---|---|---|
Market Cap | $39.40M | $77.70B |
Volume | 759,018 | 35,598,983 |
Sector | Health | — |
52-Week High | $4.64 | $305.06 |
52-Week Low | $0.68 | $229.13 |
Typical Hold Time | 37 Days | 83 Days |
Enterprise Value | -$43.28M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8157, down 6.77% today, with a bearish technical signal from moving averages. The company shows improving quarterly EPS trends, beating expectations in recent quarters, though it remains unprofitable with negative ROE and ROA. Recent FDA clearance for its epilepsy drug trial provides a positive catalyst. Analyst sentiment is bullish with 67% buy ratings.
The outlook hinges on clinical progress; upside exists if Phase 2a trials succeed, but high cash burn and lack of revenue pose significant risks. Investors should weigh the strong analyst support against the company's financial challenges and binary clinical outcomes.
IWM trades at $277.72, down 1.27% amid broader small-cap weakness. Technical indicators show a bearish trend with resistance at $278 and support at $275. The ETF faces headwinds from Federal Reserve rate hikes and underperformance relative to large-cap indices over the past decade. Recent news highlights concerns about small-cap risk premiums and competition from more selective small-cap funds.
The outlook remains cautious as rising interest rates pressure small-cap valuations. Opportunities exist for long-term investors seeking diversification from tech-heavy large caps, but near-term risks include economic sensitivity and narrow market breadth. The bearish technical setup suggests further downside potential unless macroeconomic conditions improve.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About iShares Russell 2000 ETF
The ETF is designed to track the performance of the securities and the stocks in the Russell 2000 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on IWM →
